

# Defensin

S.Priyanka

First year BDS, Saveetha dental college and hospitals

**Abstract:**

Defensin is a small amino acid (cysteine) rich cationic proteins. The another name for defensin is HUMAN NEUTROPHIL PEPTIDES (HNP). They are found in both vertebrates and invertebrates and also in plants. Defensins are endogenous antimicrobial peptides (AMPs) produced by phagocytes and epithelial cells. They have multiple functions in host defence. The other activities such as chemoattraction of a range of different cell types to sites of inflammation. They are classified into alpha, beta, theta defensins. They play a role in mucosal defense. They act as natural inhibitors of HIV-1 infection. They are antibiotic peptides.

**Key words:**

Epigenetics, DNA methylation, Defensin gene expression

**INTRODUCTION:**

The human genome encodes at least 35 different defensin peptides which belong to two structurally different subfamilies,  $\alpha$ - and  $\beta$ -defensins [1,2]. Human  $\alpha$ -defensin genes and several  $\beta$ -defensin genes are clustered on the short arm of chromosome 8. Four of the six human  $\alpha$ -defensin peptides, human neutrophil peptides (HNPs) 1–4, are found chiefly in neutrophils and other leukocytes. The other two, human  $\alpha$ -defensin 5 and 6 (HD5 and HD6), are expressed in the small intestine by paneth cell [3]. HD5 is also produced in female genital tract by epithelial cells [4]. Defensins are universal antimicrobial peptide products of neutrophils ( $\alpha$ -defensins) and epithelia ( $\beta$ -defensins) [5,6]. Defensins are 4kDa cationic peptides with a characteristic six cysteine/three disulfide bridge pattern and three domains present in a flexible aminoterminal loop, a central  $\alpha$ -helix and a carboxy-terminal antiparallel  $\beta$  sheet [7].

hBD-3 is an antimicrobial peptide which contains chemotactic and immunomodulatory properties [8-12].  $\alpha$ -Defensins are cationic molecules produced by epithelial cells; these molecules have antimicrobial, as well as immunomodulatory activity [13-16]. Of the first three hBDs hBD-1, hBD-2, and hBD-3—hBD-3 has the greatest positive charge, the widest range of antimicrobial activity, and is the most salt-tolerant [17, 18]. hBD-3, like other AMPs, it does not damage host cell membranes while inflicting fatal membrane disruption to bacterial cells. The outer leaflet of bacterial membranes contains high numbers of negatively charged phospholipids, whereas eukaryotic outer leaflets contain neutral phospholipids as well as cholesterol [19]. These differences may no less than partially, account for the capacity of AMPs to kill microbes but not host cells [20].

**STRUCTURE:**

Defensins are crystal in structure, based on a central, three-stranded  $\beta$ -sheet core in spite of different sizes, residue distributions, and cysteine-pairing schemes. In mammalian peptides, the structures of various  $\alpha$ -defensins and BDs have been determined, and it appears that each group represents a conserved scaffold, where the folding is apparently determined by the formation of the disulfides. This conserved, tertiary-structure scaffold allows the molecules to display considerably different surfaces and a

remarkable variation of cationicity, which ranges from neutral in mouse BD-2 to 11 in human BD-3. They reflect on their quaternary structure; some defensins form dimeric or oligomeric structures and monomeric [21]. The mature peptides of defensins are 30–45 amino acids in length and are amphipathic. Their net positive surface charge implies an initial electrostatic interaction between the peptide and negatively charged components of the bacterial cell wall, e.g. lipopolysaccharide or teichoic acid [22]. Four of these peptides, called human BD1 (hBD1; DEFB1), hBD2 (DEFB4), hBD3 (DEFB103A), and hBD4 (DEFB104), are mainly expressed by respiratory, gastrointestinal, and urogenital epithelial cells [23]. All four hBDs are cationic and 36 to 45 amino acids long and show similar folding and an invariable six-cysteine motif that gives rise to three disulfide bonds [24-28].

**SIGNIFICANCE:**

Once activated, most of the cells involved in both innate and cognate immune responses secrete soluble factors, including cytokines, chemokines, antibiotic peptides, which can directly irritate infectious microorganisms and/or contribute to the recruitment and activation of other immune cells [29,30]. In HIV infection, various host-derived soluble factors with antiviral activity have been described, which act by both specific and nonspecific mechanisms. These include chemokines such as RANTES, MIP-1 $\alpha$ , and MIP-1 $\beta$  [31], cytokines such as the interferons, IL-10, IL-13, IL-16 [32]. Neutrophilic granulocytes are the major producers of  $\alpha$ -defensins, which are stored at very high concentration in their azurophilic granules [33]. Neutrophils, the most abundant leukocytes in the circulation, are the first cells to infiltrate inflammatory sites and prominent components of inflammatory responses induced by viral infections [34-36]. The potential for hBD-3 to mediate APC activation may be important in bridging innate and adaptive defense mechanisms; hBD-3 also has antiviral effects, including an ability to cause down-modulation of HIV coreceptor (CXCR4) expression and to neutralize virions directly [37-39]. Microbial products which cross the gut barrier are found at a higher concentration in plasma of HIV-infected persons compared with healthy donors [40-42]. Defensins can provide chemotactic signals to a variety of cells, including APCs at nanomolar concentration [43-45].

### ROLE OF DEFENSINS IN HUMAN HEALTH:

Monocytes are recruited into inflamed tissues where these cells mature and mediate effect or functions[46,47]. hBD-3, at nanomolar concentrations, recruits monocytes via CCR2. hBD-3 induces maturation of these cells at micromolar concentration [48]. In certain diseases, i.e., psoriasis [49] and solid tumors [46], hBD-3 is found at high concentrations which cause the effects that may include membrane disruption leading to repair or death, as determined by the concentration of peptide. The role of antimicrobial peptides in bridging innate and adaptive defenses is becoming increasingly recognized. HBD-3 is expressed in the basal layer of the epithelium, there it may have greater access to submucosal tissues. At nanomolar concentration, HBD-3 causes chemotaxis via CCR2 interactions [50,51], and at higher concentrations, hBD-3 can mediate antimicrobial activity [52 -54] and APCs [55,56]

### CONCLUSION:

Defensins are cationic proteins with multiple functions in host defence. Further research is required to investigate the properties and biological significance of defensins to give a broader and clear picture of its role in host defence.

### REFERENCES :

- 1.. Ganz, T. 2003. Defensins: antimicrobial peptides of innate immunity. *Nat. Rev. Immunol.* 3: 710–720.
- 2.. Schutte, B. C., J. P. Mitros, J. A. Bartlett, J. D. Walters, H. P. Jia, M. J. Welsh, T. L. Casavant, and P. B. McCray, Jr. 2002. Discovery of five conserved  $\beta$ -defensin gene clusters using a computational search strategy. *Proc. Natl. Acad. Sci. USA* 99: 2129–2133.
- 3.. Mallow, E. B., A. Harris, N. Salzman, J. P. Russell, R. J. DeBerardinis, E. Ruchelli, and C. L. Bevins. 1996. Human enteric defensins. Gene structure and developmental expression. *J. Biol. Chem.* 271: 4038–4045.
- 4.. Quayle, A. J., E. M. Porter, A. A. Nussbaum, Y. M. Wang, C. Brabec, K. P. Yip, and S. C. Mok. 1998. Gene expression, immunolocalization, and secretion of human defensin-5 in human female reproductive tract. *Am. J. Pathol.* 152: 1247–1258.
- 5.. Diamond, G., Zasloff, M., Eck, H., Brasseur, M., Maloy, W. L. & Bevins, C. L. (1991) *Proc. Natl. Acad. Sci. USA* **88**, 3952–3956.
- 6.. Goldman, M. J., Anderson, M. G., Stolzenberg, E. D., Kari, P. U., Zasloff, M. & Wilson, J. M. (1997) *Cell* **88**, 1–9.
- 7.. Hoffmann and Hetru, 1992; Hetru *et al.*, 1998; Bulet *et al.*, 1999.
- 8.. Garcia, J. R., Jaumann, F., Schulz, S., Krause, A., Rodriguez-Jimenez, J., VForssmann, U., Adermann, K., Kluver, E., Vogelmeier, C., Becker, D., Hedrich, R., Forssmann, W. G., Bals, R. (2001) Identification of a novel, multifunctional  $\beta$ -defensin (human  $\beta$ -defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of *Xenopus oocytes* and the induction of macrophage chemoattraction. *Cell Tissue Res.* **306**, 257–264.
- 9.. Harder, J., Bartels, J., Christophers, E., Schroder, J. M. (2001) Isolation and characterization of human  $\beta$ -defensin-3, a novel human inducible peptide antibiotic. *J. Biol. Chem.* **276**, 5707–5713.
- 10.. Jin, G., Kawsar, H. I., Hirsch, S. A., Zeng, C., Jia, X., Feng, Z., Ghosh, S. K., Zheng, Q. Y., Zhou, A., McIntyre, T. M., Weinberg, A. (2010) An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis. *PLoS ONE* **5**, e10993.
- 11.. Rohrl, J., Yang, D., Oppenheim, J. J., Hehlgans, T. (2010) Human  $\beta$ -defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2. *J. Immunol.* **184**, 6688–6694.
- 12.. Wu, Z., Hoover, D. M., Yang, D., Boulegue, C., Santamaria, F., Oppenheim, J. J., Lubkowski, J., Lu, W. (2003) Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human  $\beta$ -defensin 3. *Proc. Natl. Acad. Sci. USA* **100**, 8880–8885.
- 13.. Garcia, J. R., U., Adermann, K., Kluver, E., Vogelmeier, C., Becker, D., Hedrich, R., Forssmann, W. G., Bals, R. (2001) Identification of a novel, multifunctional  $\beta$ -defensin (human  $\beta$ -defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of *Xenopus oocytes* and the induction of macrophage chemoattraction. *Cell Tissue Res.* **306**, 257–264.
- 14.. Yang, D., Chertov, O., Bykovskaya, S. N., Chen, Q., Buffo, M. J., Shogan, J., Anderson, M., Schroder, J. M., Wang, J. M., Howard, O. M., Oppenheim, J. J. (1999)  $\beta$ -Defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. *Science* **286**, 525–528.
- 15.. Niyonsaba, F., Ushio, H., Nakano, N., Ng, W., Sayama, K., Hashimoto, K., Nagaoka, I., Okumura, K., Ogawa, H. (2007) Antimicrobial peptides human  $\beta$ -defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. *J. Invest. Dermatol.* **127**, 594–604.
- 16.. Chen, X., Niyonsaba, F., Ushio, H., Hara, M., Yokoi, H., Matsumoto, K., Saito, H., Nagaoka, I., Ikeda, S., Okumura, K., Ogawa, H. (2007) Antimicrobial peptides human  $\beta$ -defensin (hBD)-3 and hBD-4 activate mast cells and increase skin vascular permeability. *Eur. J. Immunol.* **37**, 434–444.
- 17.. Harder, J., Bartels, J., Christophers, E., Schroder, J. M. (2001) Isolation and characterization of human  $\beta$ -defensin-3, a novel human inducible peptide antibiotic. *J. Biol. Chem.* **276**, 5707–5713.
- 18.. Schibli, D. J., Hunter, H. N., Aseyev, V., Starner, T. D., Wiencek, J. M., McCray, P. B., Jr., Tack, B. F., Vogel, H. J. (2002) The solution structures of the human  $\beta$ -defensins lead to a better understanding of the potent bactericidal activity of hBD3 against *Staphylococcus aureus*. *J. Biol. Chem.* **277**, 8279–8289.
- 19.. Matsuzaki, K. (1999) Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. *Biochim. Biophys. Acta* **1462**, 1–10.
- 20.. Zasloff, M. (2002) Antimicrobial peptides of multicellular organisms. *Nature* **415**, 389–395.
- 21.. Andreu, D., Rivas, L. (1998) Animal antimicrobial peptides: an overview *Biopolymers* **47**, 415–433.
- 22.. Hancock, R. E. W., and Chapple, D. S. (1999) *Antimicrob. Agents Chemother.* **43**, 1317–1323.
- 23.. Pazzier, M., D. M. Hoover, D. Yang, W. Lu, and J. Lubkowski. 2006. Human beta-defensins. *Cell. Mol. Life Sci.* **63**:1294–1313.
- 24.. Bauer, F., K. Schweimer, E. Kluver, J.-R. Conejo-Garcia, W.-G. Frossmann, P. Rosch, K. Adermann, and H. Sticht. 2001. Structure determination of human and murine beta-defensins reveals structural conservation in the absence of significant sequence similarity. *Protein Sci.* **10**:2470–2479.
- 25.. Hoover, D. M., O. Chertov, and J. Lubkowski. 2001. The structure of human beta-defensin-1: new insights into structural properties of beta-defensins. *J. Biol. Chem.* **276**:39021–39026.
- 26.. Hoover, D. M., K. R. Rajashankar, R. Blumenthal, A. Puri, J. J. Oppenheim, O. Chertov, and J. Lubkovski. 2000. The structure of human beta-defensin-2 shows evidence of higher order oligomerization. *J. Biol. Chem.* **275**:32911–32918.
- 27.. Sawai, M. V., H. P. Jia, L. Liu, V. Aseyev, J. M. Wiencek, P. B. McCray, Jr., T. Ganz, W. R. Kearney, and B. F. Tack. 2001. The NMR structure of human beta-defensin-2 reveals a novel alpha-helical segment. *Biochemistry* **40**:3810–3816.
- 28.. Schibli, D. J., H. N. Hunter, V. Aseyev, T. D. Starner, J. M. Wiencek, P. B. McCray, Jr., B. F. Tack, and H. J. Vogel. 2002. The solution structures of the activity of HBD3 against *Staphylococcus aureus*. *J. Biol. Chem.* **277**: 8279–8289.
- 29.. Ganz T. Defensins: antimicrobial peptides of innate immunity. *Nat Rev Immunol.* 2003;3:710- 720.
- 30.. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. *Annu Rev Immunol.* 2001;19:65-91.
- 31.. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 $\alpha$ , and MIP-1 $\beta$  as the major HIV-suppressive factors produced by CD8 $\pm$  T cells. *Science*. 1995;270:1811-1815.
- 32.. Kinter A, Arthos J, Cicila C, Fauci AS. Chemokines, cytokines and HIV: a complex network of interactions that influence HIV pathogenesis. *Immunol Rev*. 2000;177:88-98.
- 33.. Ganz T. Defensins: antimicrobial peptides of innate immunity. *Nat Rev Immunol.* 2003;3:710-720.
- 34.. Milligan GN. Neutrophils aid in protection of the vaginal mucosae of immune mice against challenge with herpes simplex virus type 2. *J Virol*. 1999;73:6380-6386.

35. Thomas J, Gangappa S, Kanangat S, Rouse BT. On the essential involvement of neutrophils in the immunopathologic disease: herpetic stromal keratitis. *J Immunol.* 1997;158:1383-1391.
36. Tumpey TM, Chen SH, Oakes JE, Lausch RN. Neutrophil-mediated suppression of virus replication after herpes simplex virus type 1 infection of the murine cornea. *J Virol.* 1996;70:898-904.
37. Feng, Z., Dubyak, G. R., Lederman, M. M., Weinberg, A. (2006) Cutting edge: human  $\beta$ -defensin 3—a novel antagonist of the HIV-1 coreceptor CXCR4. *J. Immunol.* **177**, 782-786.
38. Sun, L., Finnegan, C. M., Kish-Catalone, T., Blumenthal, R., Garzino-Demo, P., La Terra Maggiore, G. M., Berrone, S., Kleinman, C., Wu, Z., Abdelwahab, S., Lu, W., Garzino-Demo, A. (2005) Human  $\beta$ -defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. *J. Virol.* **79**, 14318-14329.
39. Quinones-Mateu, M. E., Lederman, M. M., Feng, Z., Chakraborty, B., Weber, J., Rangel, H. R., Marotta, M. L., Mirza, M., Jiang, B., Kiser, P., Medvik, K., Sieg, S. F., Weinberg, A. (2003) Human epithelial  $\beta$ -defensins 2 and 3 inhibit HIV-1 replication. *AIDS* **17**, F39-F48, 4109-4119.
40. Brenchley, J. M., Price, D. A., Schacker, T. W., Asher, T. E., Silvestri, G., Rao, S., Kazzaz, Z., Bornstein, E., Lambotte, O., Altmann, D., Blazar, B. R., Rodriguez, B., Teixeira-Johnson, L., Landay, A., Martin, J. N., Hecht, F. M., Picker, L. J., Lederman, M. M., Deeks, S. G., Douek, D. C. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. *Nat. Med.* **12**, 1365-1371.
41. Jiang, W., Lederman, M. M., Hunt, P., Sieg, S. F., Haley, K., Rodriguez, B., Landay, A., Martin, J., Sinclair, E., Asher, A. I., Deeks, S. G., Douek, D. C., Brenchley, J. M. (2009) Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. *J. Infect. Dis.* **199**, 1177-1185.
42. Marchetti, G., Bellistri, G. M., Borghi, E., Tincati, C., Ferramosca, S., La Francesca, M., Morace, G., Gori, A., Monforte, A. D. (2008) Microbial translocation is associated with sustained failure in CD4 $^+$  T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. *AIDS* **22**, 2035-2038.
43. Garcia, J. R., Jaumann, F., Schulz, S., Krause, A., Rodriguez-Jimenez, J., Forssmann, U., Adermann, K., Kluver, E., Vogelmeier, C., Becker, D., Hedrich, R., Forssmann, W. G., Bals, R. (2001) Identification of a novel, multifunctional  $\alpha$ -defensin (human  $\beta$ -defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of *Xenopus oocytes* and the induction of macrophage chemoattraction. *Cell Tissue Res.* **306**, 257-264.
44. Wu, Z., Hoover, D. M., Yang, D., Boulegue, C., Santamaria, F., Oppenheim, J. J., Lubkowski, J., Lu, W. (2003) Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human  $\beta$ -defensin 3. *Proc. Natl. Acad. Sci. USA* **100**, 8880-8885.
45. Jin, G., Kawsar, H. I., Hirsch, S. A., Zeng, C., Jia, X., Feng, Z., Ghosh, S. K., Zheng, Q. Y., Zhou, A., McIntyre, T. M., Weinberg, A. (2010) An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis. *PLoS One* **5**, e10993.
46. Jin, G., Kawsar, H. I., Hirsch, S. A., Zeng, C., Jia, X., Feng, Z., Ghosh, S. K., Zheng, Q. Y., Zhou, A., McIntyre, T. M., Weinberg, A. (2010) An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis. *PLoS One* **5**, e10993.
47. Rohrl, J., Yang, D., Oppenheim, J. J., Hehlgans, T. (2010) Human  $\beta$ -defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2. *J. Immunol.* **184**, 6688-6694.
48. Funderburg, N., Lederman, M. M., Feng, Z., Drage, M. G., Jadlowsky, J., Harding, C. V., Weinberg, A., Sieg, S. F. (2007) Human  $\beta$ -defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. *Proc. Natl. Acad. Sci. USA* **104**, 18631-18635.
49. Harder, J., Bartels, J., Christophers, E., Schroder, J. M. (2001) Isolation and characterization of human  $\beta$ -defensin-3, a novel human inducible peptide antibiotic
50. Jin, G., Kawsar, H. I., Hirsch, S. A., Zeng, C., Jia, X., Feng, Z., Ghosh, S. K., Zheng, Q. Y., Zhou, A., McIntyre, T. M., Weinberg, A. (2010) An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis. *PLoS ONE* **5**, e10993.
51. Rohrl, J., Yang, D., Oppenheim, J. J., Hehlgans, T. (2010) Human  $\beta$ -defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2. *J. Immunol.* **184**, 6688-6694. *PLoS ONE* **5**, e10993.
52. Garcia, J. R., Jaumann, F., Schulz, S., Krause, A., Rodriguez-Jimenez, J., Forssmann, U., Adermann, K., Kluver, E., Vogelmeier, C., Becker, D., Hedrich, R., Forssmann, W. G., Bals, R. (2001) Identification of a novel, multifunctional  $\beta$ -defensin (human  $\beta$ -defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of *Xenopus oocytes* and the induction of macrophage chemoattraction. *Cell Tissue Res.* **306**, 257-264.
53. Harder, J., Bartels, J., Christophers, E., Schroder, J. M. (2001) Isolation and characterization of human  $\beta$ -defensin-3, a novel human inducible peptide antibiotic. *J. Biol. Chem.* **276**, 5707-5713.
54. Wu, Z., Hoover, D. M., Yang, D., Boulegue, C., Santamaria, F., Oppenheim, J. J., Lubkowski, J., Lu, W. (2003) Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human  $\beta$ -defensin 3. *Proc. Natl. Acad. Sci. USA* **100**, 8880-8885.
55. Funderburg, N., Lederman, M. M., Feng, Z., Drage, M. G., Jadlowsky, J., Harding, C. V., Weinberg, A., Sieg, S. F. (2007) Human  $\beta$ -defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. *Proc. Natl. Acad. Sci. USA* **104**, 18631-18635.
56. Funderburg, N. T., Jadlowsky, J. K., Lederman, M. M., Feng, Z., Weinberg, A., Sieg, S. F. (2011) The Toll-like receptor 1/2 agonists Pam(3) CSK(4) and human  $\beta$ -defensin-3 differentially induce interleukin-10 and nuclear factor- $\kappa$ B signalling patterns in human monocytes. *Immunology* **134**, 151-160.